Hyden 80 mg Tablet (Valsartan)
Valsartan
Prescription medication
Samik Pharmaceutical Co., Ltd.
MFDS item code 201802474 · Approved 2018.06.15
This product's status changed to Expired on 2023.06.15. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used for the treatment of essential hypertension and heart failure. It is particularly effective in heart failure patients who are intolerant to ACE inhibitors. Additionally, it helps to lower the risk of death in stable patients with left ventricular dysfunction after myocardial infarction. This medication plays an important role in managing cardiovascular diseases and is used to protect the patient's life.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended to take the medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases, depending on patient tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or higher. However, this medicine should not be administered to patients with creatinine clearance below 10 mL/min or patients on dialysis, because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Essential hypertension: Safety and efficacy have not been established in children and adolescents under 18 years of age. Heart failure and reduction of the risk of death after myocardial infarction: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. It should not be used by women who are pregnant, may become pregnant, or are breastfeeding. The use of this medication is not recommended for patients with severely impaired liver function or severe kidney dysfunction. Patients with a history of allergic reactions or hereditary angioedema should not take this medication. Elderly patients, those with elevated serum potassium levels, and patients with mildly impaired liver function should be particularly cautious when taking this medication, and dosage adjustments may be necessary. This medication can have a strong blood pressure-lowering effect, and dizziness or hypotension may occur upon initial use, so if symptoms are severe, consult a doctor immediately. When taken with other antihypertensives or diuretics, the potassium levels in the blood may increase dangerously, so patients must inform their doctor and have regular blood tests. Regular monitoring of kidney function and electrolyte status is important while taking this medication. Dizziness may occur during driving or operating machinery, so caution is advised. In case of overdose, severe hypotension, decreased consciousness, shock, etc., may occur, and immediate emergency treatment is required. The safety and efficacy in children and adolescents under 18 years have not been established, so it is advisable not to use it.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is best to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Light reddish round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan
Prescription medication
Samik Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.